Novacyt S.A. (AIM: NCYT)

Market Cap	49.90M
Revenue (ttm)	11.58M
Net Income (ttm)	-28.29M
Shares Out	n/a
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135,131
Open	69.00
Previous Close	69.40
Day's Range	69.00 - 74.20
52-Week Range	39.07 - 137.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 26, 2024

About Novacyt

Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Yourgene Health, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screeni...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 237
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: NCYT

Financial Performance

In 2023, Novacyt's revenue was 11.58 million, a decrease of -44.97% compared to the previous year's 21.04 million. Losses were -28.29 million, 9.96% more than in 2022.